Convenience drives research into transdermal patches, sublingual formulations, and improved oral delivery systems
GLP-1 receptor agonist medications solve this by using modified versions of the GLP-1 molecule that resist enzymatic breakdown
It supports detoxification, improves skin clarity, boosts immunity, reduces inflammation, and enhances cellular energy production
There are several Phase 3 trials evaluating GLP-1s for conditions, such as metabolic dysfunction-associated steatohepatitis (MASH), prediabetes, Alzheimer's disease, diabetic retinopathy and osteoarthritis of the knee (in patients with obesity)
For your further reading: For your further reading: For your further reading: 28 Dunn, Jacob, and Michael H
doi: 10.3389/fphar.2026.1795174 Received 24 January 2026 Revised 09 April 2026 Accepted 13 April 2026 Published 30 April 2026 Volume 17 - 2026 Edited by Nabil Eid, IMU University, Malaysia Reviewed by MoezAlIslam Ezzat Faris, Applied Science Private University, Jordan Payal Bhatnagar, International Medical University, Malaysia Gehan El Akabawy, Ajman University, United Arab Emirates Updates Copyright 2026 Ma, Hao, Wang, Qiu, Cao, Deng, Wang, Li, Zhang, Wei, Yao, Gao, Yi, Liu and Li